November 26, 2022 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, will present data on Elucirem (gadopiclenol) injection, Dotarem (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting.
"It's very exciting to be back at RSNA, to give the radiology community a first-hand opportunity to experience the clarity of MRI images offered by our new MRI product, Elucirem," said David Hale, Chief Executive Officer of the Guerbet Group. "We look forward to sharing insights about gadopiclenol, a novel, highly stable macrocyclic gadolinium-based contrast agent offering the highest relaxivity in its class for magnetic resonance imaging.2"
Elucirem is indicated for use with MRI in adults and pediatric patients aged two years and older to detect and visualize lesions in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis and musculoskeletal system).1
For Elucirem, Guerbet received Priority Review by the US Food and Drug Administration (FDA) on the basis of the unmet medical needs, as there are currently no U.S. approved and marketed MRI contrast agents indicated for musculoskeletal lesion visualization and no macrocyclic GBCAs approved broadly to visualize lesions located throughout the body.3 Guerbet received US FDA's marketing approval for Elucirem on September 21, 2022.
Elucirem (gadopiclenol) injection will be available in glass vials, glass pharmacy bulk packages and in plastic pre-filled syringes, which can help to streamline workflow in the imaging suite. All gadopiclenol is manufactured by Guerbet Group Company.
ELUCIREM (gadopiclenol) injection and DOTAREM (gadoterate meglumine) injection Important Safety Information
|
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF) See full prescribing information for complete boxed warning Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
|
Opportunities to Learn More at RSNA 2022
RSNA Innovation Theater -- @ 1:00 – 1:15 p.m. CST, Monday November 28, 2022: Aashim Bhatia, MD, MS, Assistant Professor in Radiology and Pediatric Neuroradiologist at the Children's Hospital of Philadelphia will be presenting Guerbet's Latest Innovation: Illuminating the Possibilities with a Novel New Drug https://eppro02.ativ.me/web/planner.?id=RSNA22&table=agenda&tid=S1138
Oral and Poster Presentations:
|
Title |
Author(s) |
Date/Time |
Session Number |
|
Reduced Body Gd Exposure over 5 months after a single Human Equivalent Dose of Gadopiclenol as compared to Gadobutrol in Healthy Rats |
M. Rasschaert, C. Eoulourmyl Strzeminska, C. Walton, M. Lefebvre, N. Decout, C. Factor, P. Robert |
Dec. 1 – 12:15 p.m. – 12:45 p.m. |
RSA-SPNPM |
|
Efficacy and safety of gadopiclenol for central nervous system (CNS) magnetic resonance imaging (MRI): The Picture Trial |
Leo Wolansky |
Nov. 30 1:30 p.m. – 2:30 p.m. |
W6 – SSNR13 |
|
Efficacy and safety of gadopiclenol for central nervous system (CNS) magnetic resonance imaging (MTI): The Picture Trial |
Christiane Kuhl |
Nov. 27 2:30 p.m. – 3:30 p.m. |
S5 – SSMSO1 |
|
Use of real life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure |
Imran Shahid, Eric Lancelot |
Dec. 1 12:15 p.m. – 12:45 p.m. |
R5A - SPNR |
|
Super-dose: a deep learning method to increase the sensitivity of MRI in neuro-oncology via virtual dose amplification |
Alexandre Bone Dr. Samy Ammari |
Thu. Nov. 30 12:45 p.m. – 1:15 p.m. |
W5B - SPNR |
|
Multi-head deep learning model for the detection of prostate cancer lesions in bi-parametric MRI |
Kourosh Jafari-Khouzani, Maria Victoria Sainz de Cea, Wen Wei, Aly Mohamed, Noelle Debs, Alexandre Routier, Onofrio Caralano, Marwan Sati, Amin Katouzian |
Tue, Nov. 29 12:45pm - 1:15pm Scientific Poster Sessions |
Learning Center – IN DPS T5B-SPIN-4 |
|
Comparison of three methods for lesion detection and classification on bi-parametric MRI |
Maria V. Sainz de Cea, Kourosh Jafari-Khouzani, Wen Wei, Aly A. Mohamed, Noelie Debs, Alexandre Routier, Marc-Michel Rohe, Russell Klenk, Onofrio Catalano, Amin Katouzian |
Tue, Nov. 29 9:00am - 9:30am Scientific Poster Sessions |
T2-SPGU-3 |
|
Rigorous Comparison of a New Fully Automated Deep Learning Algorithm for Detection of Focal Liver Lesions in Abdominal Contrast CT with Radiologists |
Dufort, G. Palma, P. L. Esquinas Fernandez, Y. Wang, O. Bonakdar Sakhi, F. C. Commandeur, A. Sitek, F. Louvet-De Verchere, K. Siewert, K. Tipton |
Tue, Nov. 29 1:30pm - 2:30pm |
T6-SSGI10-4 |
Guerbet's RSNA Education & Research Award Recipient 2022
As part of its continued partnership with the Radiological Society of North America (RSNA), Guerbet is proud to announce that the RSNA Research & Education (R&E) Foundation Board of Trustees has awarded the Guerbet Research Scholar Grant to Vivek Yedavalli, MD, MS from Johns Hopkins School of Medicine. Dr. Yedavalli was awarded $75,000 per year for two years to support his study, Deep Learning Models Using Baseline Comprehensive CT Stroke Collateral Imaging in Cerebral Angiographic Collateral, Post Procedural Hemorrhagic Transformation, and Clinical Outcomes Predictions for Increasing Thrombectomy Eligibility. The RSNA R&E Foundation invests in the future of radiology by developing investigators and supporting lifelong innovative research and education.
Digital Solutions Featured at Booth #1711
Guerbet will also feature a collection of digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting:
- Dose & Care, a state-of-the-art digital solution for monitoring patient exposure to X-rays that is compatible with all types of ionizing modalities and collects data to provide a record of patient exposure
- Contrast & Care, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
- Icobrain, a cloud-based AI solution designed to quantify disease specific brain structures on MR and CT
- Galileo, an educational web-based case review platform to help train radiology residents.
For more information: www.guerbet.com
July 25, 2024 
